Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20145
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBaxevanis, C. N.en
dc.contributor.authorReclos, G. J.en
dc.contributor.authorEconomou, M.en
dc.contributor.authorArsenis, P.en
dc.contributor.authorKatsiyiannis, A.en
dc.contributor.authorSeferiades, K.en
dc.contributor.authorPapadopoulos, G.en
dc.contributor.authorTsolas, O.en
dc.contributor.authorPapamichail, M.en
dc.date.accessioned2015-11-24T19:05:06Z-
dc.date.available2015-11-24T19:05:06Z-
dc.identifier.issn0892-3973-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20145-
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectDose-Response Relationship, Immunologicen
dc.subjectHumansen
dc.subjectInterleukin-1/analysisen
dc.subjectInterleukin-2/analysisen
dc.subject*Lymphocyte Culture Test, Mixeden
dc.subjectMonocytes/drug effects/immunologyen
dc.subjectProtein Precursors/*pharmacologyen
dc.subjectT-Lymphocytes/drug effects/immunologyen
dc.subjectThymosin/*analogs & derivatives/pharmacologyen
dc.subjectTime Factorsen
dc.titleMechanism of action of prothymosin alpha in the human autologous mixed lymphocyte responseen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.3109/08923978809006448-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/2977606-
heal.identifier.secondaryhttp://informahealthcare.com/doi/abs/10.3109/08923978809006448-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1988-
heal.abstractProthymosin alpha(Prot alpha), an immunologically active polypeptide derived initially from rat thymus, and now pig thymus, was tested for its effect on autoantigen-induced human T cell proliferation in vitro. Pig ProT alpha was found to enhance the autologous mixed lymphocyte response (auto-MLR). Optimum enhancement was achieved at doses which varied among different donors. Treatment of the stimulatory monocytes with ProT alpha resulted in considerably higher auto-MLR responses as compared to those with non treated monocytes. ProT alpha was without effect on T lymphocytes. In contrast, T lymphocytes exhibited enhanced proliferative activity when treated with ProT alpha in the environment of autologous monocytes. Moreover, supernatants from cultures of monocytes incubated with ProT alpha (ProT alpha-sup) were also shown to enhance the human auto-MLR either after addition in cultures or after preincubation with responder T lymphocytes. In addition, ProT alpha-sup did not demonstrate any detectable interleukin 1 (IL 1) or interleukin 2 (IL 2) - like activity. Furthermore, ProT alpha-sup induced an increase in IL 2 production in auto-MLR cultures. The enhancement of T-cell proliferation and IL 2 production by ProT alpha-sup was maximal when this material was added at the beginning of the auto-MLR, and no effect of ProT alpha-sup was seen if the latter was added 3 days after initiation of the culture. Finally, Prot alpha-sup was also shown to increase the expression of IL 2 receptors on T lymphocytes activated in the auto-MLR. These studies suggest that ProT alpha enhances the human auto-MLR through ProT alpha-sup which is released after interaction of monocytes with ProT alpha ProT alpha-sup then increases directly T lymphocyte proliferation by elevating IL 2 production and expression of IL 2 specific receptors on autoactivated T lymphocytes.en
heal.journalNameImmunopharmacol Immunotoxicolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons